Predictive Biomarkers in Late Onset Neutropenia (LON) Associated with Rituximab

DOI: 10.14744/ejmi.2020.55639 EJMI 2020;4(4):428–432

[1]  D. Moore.  Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia. , 2016, P & T : a peer-reviewed journal for formulary management.

[2]  Katrina L. Randall.  Rituximab in autoimmune diseases. , 2016, Australian prescriber.

[3]  N. Schmitz,et al.  Suboptimal dosing of rituximab in male and female patients with DLBCL. , 2014, Blood.

[4]  R. Greil,et al.  Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response , 2012, Haematologica.

[5]  J. Palmblad,et al.  Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms , 2011, Expert review of hematology.

[6]  O. Bairey,et al.  Late-Onset Neutropenia After Rituximab Treatment: Case Series and Comprehensive Review of the Literature , 2010, Medicine.

[7]  A. Chan,et al.  Late‐onset neutropenia following RCHOP chemotherapy in diffuse large B‐cell lymphoma , 2009, American journal of hematology.

[8]  J. Palmblad,et al.  Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis , 2008, Medical oncology.

[9]  G. Rossi,et al.  Delayed-onset peripheral blood cytopenia after rituximab: Frequency and risk factor assessment in a consecutive series of 77 treatments , 2006, Leukemia & lymphoma.

[10]  P. Solal-Céligny,et al.  Neutropenia in patients treated with rituximab. , 2003, The New England journal of medicine.

[11]  A. Grigg,et al.  Delayed‐onset neutropenia associated with rituximab therapy , 2003, British journal of haematology.

[12]  K. Stamatopoulos,et al.  Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases. , 2002, Leukemia research.

[13]  S. Advani,et al.  Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Kantarjian,et al.  Rituximab dose-escalation trial in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Vose,et al.  Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Grillo‐López.  Rituximab: an insider's historical perspective. , 2000, Seminars in oncology.

[17]  Jin Hong Liu,et al.  Chronic neutropenia mediated by fas ligand. , 2000, Blood.

[18]  K. Oshimi,et al.  The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. , 1997, Blood.